GlassScriptPhysician profile
Paula Dilanchian
NPI 1477708576
$2,751.14
in general payments reported to CMS, 2019-2025
16 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $422 · 2021: $28.53 · 2022: $431 · 2023: $278 · 2024: $189 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552 · Education: $51.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.10 |
| Education | $51.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $490.91 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Allergan, INC. | $483.30 | 2019-2020 | |
| Gilead Sciences, INC. | $466.96 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $247.04 | 2019-2024 | Apretude, Dovato, Cabenuva |
| Cumberland Pharmaceuticals, INC. | $181.17 | 2022-2023 | Vibativ |
| Tetraphase Pharmaceuticals, INC. | $179.62 | 2019 | |
| Abbvie INC. | $178.21 | 2023-2024 | Avycaz |
| Janssen Biotech, INC. | $175.16 | 2020-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $107.48 | 2022-2025 | Nuzyra |
| Shionogi INC | $69.45 | 2022 | |
| Melinta Therapeutics, LLC | $51.72 | 2020-2023 | Orbactiv, Kimyrsa, Vabomere |
| Insmed, INC. | $37.82 | 2019-2025 | Brinsupri, Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $25.80 | 2020 | |
| Shire North American Group INC | $23.81 | 2019 | |
| La Jolla Pharmaceutical Company | $20.54 | 2023 | Xerava |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Dilanchian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.